| Inflammation--a new therapeutic target in pneumonia. | |
| | |
MedLine Citation:
|
PMID: 15824518 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Inflammation is a hallmark of pneumonia. Therefore, managing inflammation is an attractive adjunct to targeted antibiotic therapy, mainly in severe pneumonia. Recent investigations indicate that glucocorticoids given in physiological doses (from 10-fold to 100-fold less than doses administered in the past) could be of benefit. We could also manage inflammation by administering or influencing cytokines. A major concern is that drugs designed to target a single cytokine or receptor could prove ineffective due to the redundancy of signaling pathways involved. This may require selection of drugs with broad activity or the targeting of molecules common to inflammatory signaling pathways. Drugs affecting multiple molecules or key inflammatory pathway intermediates could be more effective, but their use will need to be weighed against the risk of impairing innate immunity. Indirect approaches to manage inflammation, such as neutralizing cytotoxic substances in the lung (e.g., inhibiting, neutralizing and eliminating endotoxin), could be used in combination with other approaches. Ideally, potential treatment of life-threatening bacterial pneumonia will combine immunoadjuvant and conventional antibiotic therapy, although intense clinical research with immunotherapy has not yet yielded a successful treatment adjunct. We believe that compounds capable of stimulating early host defense and microbial clearance, but not the later phases of inflammatory tissue injury associated with sepsis, may be advantageous. |
| | |
Authors:
|
Mario Cazzola; Maria Gabriella Matera; Gabriella Pezzuto |
Related Documents
:
|
9627168 - Thirty years of anti-mediator treatment in sepsis and septic shock--what have we learned? 15273558 - Adrenomedullin and adrenomedullin binding protein-1 attenuate vascular endothelial cell... 8280458 - Cell mediated events that control blood coagulation and vascular injury. 20593268 - Endotoxin detection--from limulus amebocyte lysate to recombinant factor c. 19441068 - Hericium erinaceum induces maturation of dendritic cells derived from human peripheral ... 8634418 - The rar-rxr as well as the rxr-rxr pathway is involved in signaling growth inhibition o... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Respiration; international review of thoracic diseases Volume: 72 ISSN: 0025-7931 ISO Abbreviation: Respiration Publication Date: 2005 Mar-Apr |
Date Detail:
|
Created Date: 2005-04-12 Completed Date: 2005-08-02 Revised Date: 2009-11-11 |
Medline Journal Info:
|
Nlm Unique ID: 0137356 Medline TA: Respiration Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 117-26 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2005 S. Karger AG, Basel. |
Affiliation:
|
Unit of Pneumology and Allergology, Department of Respiratory Medicine, A. Cardarelli Hospital, Naples, Italy. mcazzola@qubisoft.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Bacterial Agents / therapeutic use* Glucocorticoids / therapeutic use* Humans Inflammation* / drug therapy Pneumonia / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Glucocorticoids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A correlation study of endoneurial fluid pressure and electroneurography of the facial nerve.
Next Document: Do high-resolution CT findings of usual interstitial pneumonitis obviate lung biopsy? Views of pulmo...